Alligator Bioscience AB Employee Directory
Biotechnology ResearchGävleborg, Sweden11-50 Employees
Alligator Bioscience AB is a clinical-stage biotechnology company focused on developing tumor-directed antibody therapies for cancer. Its lead asset is the CD40-activating antibody mitazalimab, and its portfolio also includes collaborations such as ALG.APV-527 with Aptevo Therapeutics, Neo-X-Prime–based candidates, and RUBY bispecifics with Orion Corporation. In addition, the company has out-licensed programs, including AC101/HLX22 in Phase 2 with Shanghai Henlius Biotech, and another undisclosed target licensed to Biotheus. Alligator’s technology rests on two proprietary platforms that support antibody optimization and diversification, and the company operates from Lund, Sweden, as a small-to-mid-sized organization. In 2023 the company announced a patent for a Neo-X-Prime bispecific antibody, ATOR-4066, and reported related scientific activity, illustrating ongoing expansion of its immuno-oncology program and collaborations, including with Orion since 2021.